Peptides: what physicians need to know
News, regulation and evidence on peptides in Guyana: what the law, the regulators and the studies say, with every fact linked to its source.
Regulation
Mounjaro and Ozempic in Guyana: President says demand outpaces rules
President Irfaan Ali warned in April 2026 that cosmetic use of tirzepatide is outpacing Guyana's regulators, and the Health Minister says a generic semaglutide is coming, prescription-only. What physicians in Guyana need to know.
Read article →
Regulation
Guyana's Medicines Regulation Bill and a new pharmacovigilance centre
Guyana still regulates medicines under a 1971 law. In 2026 the government put a Medicines Regulation Bill on its legislative agenda, and with PAHO it began building a national pharmacovigilance centre at the GA-FDD. What changes for physicians.
Read article →
Regulation
Drug import permits in Guyana move online: the GA-FDD single window
Guyana's Food and Drug Department now takes drug import permits, manufacturing licences and marketing authorisation applications through the national Electronic Single Window. What it changes for imports, registration and the suitcase trade.
Read article →
Evidence
Dialysis patients double in Guyana as diabetes drives kidney failure
Guyana's Ministry of Health says the number of people on state-supported dialysis has doubled since 2020, and diabetes-related amputations are rising. What the local data and the semaglutide kidney trial mean for physicians.
Read article →
Market
Medicine shortages in Guyana: Ali's dashboard and the 90 % promise
After years of audits and complaints about stock-outs in public hospitals, Guyana made a single national drug-supply dashboard mandatory on 1 July 2026 and threatened to fire officials who buy outside it. What the record shows.
Read article →